(±)-Atenolol-d7 (Synonyms: (R,S)-Atenolol-d7, Duraatenol, ICI 66082) |
| Katalog-Nr.GC46273 |
An internal standard for the quantification of (±)-atenolol
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1202864-50-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
(±)-Atenolol-d7 is intended for use as an internal standard for the quantification of (±)-atenolol by GC- or LC-MS. (±)-Atenolol is an antagonist of the β1-adrenergic receptor (β1-AR; Ki = 1.14 µM).1 It is selective for β1-ARs over β2-ARs (Ki = 48.7 µM). (±)-Atenolol (200 mg/kg per day) delays the onset of hypertension in spontaneously hypertensive rats.2 Formulations containing atenolol have been used in the treatment of high blood pressure.
1.Golf, S., Bjornerheim, R., Erichsen, A., et al.Relative selectivity of different β-adrenoceptor antagonists for human heart β1- and β2-receptor subtypes assayed by a radioligand binding techniqueScand. J. Clin. Lab. Invest.47(7)719-723(1987) 2.Richer, C., Boissier, J.R., and Giudicelli, J.F.Chronic atenolol treatment and hypertension development in spontaneously hypertensive ratsEur. J. Pharmacol.47(4)393-400(1978)
Average Rating: 5 (Based on Reviews and 25 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *